Drug lookup | Fillwise

MOCLOBEMIDE

All products: general benefit

Other products in the same Health Canada class (N06A) — coverage varies; not interchangeable

Amitriptyline (Elavil): general benefit
Citalopram (Celexa): general benefit, Not a benefit
Clomipramine (Anafranil Tab): general benefit
Desipramine (Pertofrane): general benefit, Not a benefit
Doxepin (Sinequan): general benefit, Not a benefit
Duloxetine (Cymbalta): general benefit, Not a benefit

17 more in the class list below

Manerix · DIN 00899356 · 150mg · tablet

General benefitDormant since 2026-07-31 · checked 2026-09-20 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Manerix · DIN 00899356 Manufacturer: Meda AB; listing date 1996-10-01 Health Canada: Dormant since 2026-07-31 · brand MANERIX · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 150 MG · company Bausch health, canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.5295 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13256 · Verify on the e-Formulary ↗ (DIN 00899356)

Source record

DIN 00899356: Manerix Raw flags: sec3=Y Item: 281604067; group id 465; item number 1171; lccId None; manufacturer id MAB Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.9126; ministry $0.5295 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00899356 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13256

Interchangeable products

Moclobemide · DIN 02232150 · $0.5295

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Dormant since 2026-07-31 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS MANERIX (moclobemide) is indicated for the treatment of major depressive disorder (MDD) in adults. 1.1 Pediatrics  The safety and efficacy of MANERIX has not been studied in pediatric population (<18 years of age). Therefore, its use is not indicated in this population. 1.2 Geriatrics  No dosage adjustments are necessary in elderly patients (see 10 CLINICAL PHARMACOLOGY, Special Populations, Single and Multiple Dose). https://pdf.hres.ca/dpd_pm/00061932.PDF PM date: June 23, 2021 Source product: MANERIX; DIN 02166747; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)